



PATENT APPLICATION

File No. 97-75C1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

9-23-04

Date

Kim M. Goplen

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Paul O. Sheppard, Stephen R. Jaspers, Zeren Gao  
Serial No. : 10/011,859  
Group Art Unit : 1647  
Examiner : Spector, L.  
Filed : November 5, 2001  
For : CONNECTIVE TISSUE GROWTH FACTOR HOMOLOGS  
Date Submitted : September 23, 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.


The present application is a continuation of U.S. Patent Application Serial No. 09/253,316, filed February 19, 1999.

Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent Office in a prior application identified herein.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 26-0290.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Deborah A. Sawislak". The signature is fluid and cursive, with the first name "Deborah" being more prominent.

Deborah A. Sawislak  
Registration No. 37,438

P.T.O. 1449  
(REV. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-75C1

Serial No.  
10/011,859SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)Applicant(s):  
Paul O. Sheppard, Stephen R. Jaspers,  
Zeren GaoFiling Date:  
November 5, 2001

Group: 1647

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,194,596	3/16/93	Tischer et al.	530	399	
	5,350,836	9/27/94	Kopchick et al.	530	399	
	5,408,040	4/18/95	Grotendorst et al.	530	399	

## FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

		A. Gladwin et al., <i>Human Molecular Genetics</i> 6(1):123-127, 1997.
		N. Braveman et al., <i>Nature Genetics</i> 15:369-376, 1997.
		C.C. Pilbeam et al., "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) or malignancy on bone resorption and formation in organ culture," <i>Bone</i> 14:717-720, 1993.
		S. Vukicevic et al., "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenic protein 7)," <i>Proc. Nat. Acad. Sci. USA</i> 93:9021-9026, 1996.
		J. Massague, "The TGF- $\beta$ family of growth and differentiation factors," <i>Cell</i> 49:437-438, 1987.
		L.E. Benjamin et al., "A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," <i>Development</i> 125:
		J. Skoinick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech</i> 18(1):34-39, 2000.
		P. Bork, "Powers and pitfalls in sequence analysis: The 70% hurdle," <i>Genome Research</i> 10:398-400, 2000.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)	File No. 97-75C1	Serial No. 10/011,859
	Applicant(s): Paul O. Sheppard, Stephen R. Jaspers, Zeren Gao	
	Filing Date: November 5, 2001	Group: 1647

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

		T. Doerks et al., "Protein annotation: detective work for function prediction," <i>Trends in Genetics</i> 4(g):248-250, June 1998.
		T.F. Smith et al., "The challenges of genome sequence annotation or "The devil is in the details," <i>Nature Biotechnology</i> 15:1222-1223, 1997.
		S.E. Brenner, "Errors in genome annotation," <i>Trends in Genetics</i> 15(4):132-133, 1999.
		P. Bork, "Go hunting in sequence databases but watch out for the traps," <i>Trends in Genetics</i> 12(10):425-426, 1996.
		R. Strausberg, Loci AW592899 and AA592984, 1997, National Cancer Institute Cancer Genome Anatomy Project, Tumor Gene Index, Accessed 8/21/00

Examiner	Date considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.